epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
pharma · Major Depression Disorder · Major Depression Disorders
Mylan Specialty
Mylan Pharma UK
Mylan Specialty drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
napa, USA HQ
233 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- napa, USA
- Employees
- 233
- Programs
- 4
- Drugs
- 10
- Patents
- 0
Mylan Specialty pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Mylan Specialty drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
Development asset linked to Mylan Specialty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bile acid receptor.
- Target
- Bile acid receptor
- Mechanism
- Bile acid receptor FXR agonist